Trontinemab for people at risk of Alzheimer's symptoms
Part of Brain & nervous system, Mental health clinical trials.
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a study partner, like a family member or friend, who can join you at visits.
- You need to weigh 330 pounds (150 kilograms) or less.
- You must have a certain level of a protein in your blood (pTau217) that points to future Alzheimer's risk.
- You cannot have any memory or thinking problems, including mild cognitive impairment or dementia.
- You cannot have had a stroke, major head injury, or certain brain conditions in the past year.
- You cannot take certain medications, like blood thinners, Alzheimer's drugs, or antipsychotics, unless approved by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.